Clinical trial
Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for…
NCT00010426 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00010426 |
|---|---|
| Title | Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Collaborators | Leadiant Biosciences, Inc. Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cystinosis |
| Intervention type | Drug |
| Interventions | cysteamine hydrochloride |
| Enrollment | 30 |
| Start date | Dec 1, 1999 |
| Completion | Feb 1, 2001 |
| First posted | Feb 2, 2001 |
| Last update posted | Mar 25, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: